It was recently demonstrated that the performance of the FIB-4 index in predicting advanced fibrosis in NAFLD cases was better than that of other non-invasive markers, such as the AST/ALT ratio, cirrhosis determinant score, AST/platelet ratio, Goteburg university cirrhosis index, AST/platelet ratio index, BARD score, and NAFLD fibrosis score [16]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.